Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.31
−$0.06 · -2.53%
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Previous close
$2.31
−$0.06 · -2.53%
Regular session · ET · Market data may be delayed.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $2.31
52-week range
Current $2.31
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
45
Fair Value
Sentiment
69
Bullish
Risk
64
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Day range
Current $2.31
52-week range
Current $2.31
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 23, 2025 | 1:30 | — | — |
Stock split | Jul 21, 2022 | 1:10 | — | — |
Stock split | Jul 16, 2018 | 1:10 | — | — |
Stock split | Mar 6, 2016 | 1:10 | — | — |
Stock split | Jun 15, 2014 | 1:20 | — | — |
Stock split | Apr 10, 2011 | 1:153 | — | — |
Effective Jun 23, 2025
1:30
Effective Jul 21, 2022
1:10
Effective Jul 16, 2018
1:10
Effective Mar 6, 2016
1:10
Effective Jun 15, 2014
1:20
Effective Apr 10, 2011
1:153
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
